Dr. Reddy's Laboratories launches Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe, a therapeutic equivalent generic version of Faslodex® (fulvestrant) Injection, 250 mg/5 mL (50 mg/mL), approved by the U.S. Food and Drug Administration (USFDA).

The Faslodex® brand and generic market had U.S. sales of approximately $407 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Dr. Reddy's Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe is available in a carton containing two 5 mL single-dose prefilled syringes.

Faslodex® is a trademark of the AstraZeneca group of companies.

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.4434 as compared to the previous close of Rs. 4323.15. The total number of shares traded during the day was 38801 in over 4626 trades.

The stock hit an intraday high of Rs. 4434.05 and intraday low of 4298.45. The net turnover during the day was Rs. 169776659.

Source : Equity Bulls

Keywords